驱动蛋白Eg5在非小细胞肺癌中的表达及其意义  

The expression and significance of kinesin Eg5 in non-small cell lung cancer

作　　者：袁艳龙[1] 赵静雅[1] 孙颖[1] 王静[1] 宋晓明[1] 郭卫东[1] 

机构地区：[1]邯郸市中心医院病理科,河北邯郸056001

出　　处：《现代肿瘤医学》2017年第4期558-561,共4页Journal of Modern Oncology

基　　金：邯郸市科学技术研究与发展计划项目(编号:1323108087-4)

摘　　要：目的:检测驱动蛋白Eg5在非小细胞肺癌(NSCLC)中的表达水平,并探讨其与非小细胞肺癌转移的关系。方法:选取63例非小细胞肺癌的手术切除标本和20例正常肺脏组织标本,采用免疫组化检测Eg5的表达,并分析其与非小细胞肺癌临床病理特征和转移之间的关系。结果:Eg5在正常肺组织中未见明显表达,在非小细胞肺癌组织中的表达阳性率为68.3%(43/63),且与非小细胞肺癌的肿瘤直径(χ~2=4.506,P=0.034)、临床分期(χ~2=8.866,P=0.012)、淋巴结转移情况(χ~2=19.52,P<0.001)有关,差异有统计学意义;而与患者性别、年龄、分化程度等指标无明显的相关性(P>0.05)。结论:Eg5在正常肺组织中未见明显表达,在非小细胞肺癌组织中高表达,Eg5的表达与非小细胞肺癌临床分期及转移有关,Eg5可预测非小细胞肺癌的淋巴结转移情况,可能作为非小细胞肺癌化学治疗的潜在靶点。Objective： To investigate the expression level of kinesin Eg5 in non- small cell lung cancer（ NSCLC）,and to explore its relation with metastasis of non- small cell lung cancer. Methods： To select 63 cases with non-small cell lung cancer surgical resection specimens and 20 cases of normal lung tissue samples,Eg5 expression was detected by immunohistochemistry,and its relation with clinical pathological features and metastasis of non- small cell lung cancer was analysed. Results： Immunohistochemistry showed Eg5 in normal lung tissue was not- obviously expressed,in non- small cell lung cancer overall expression positive rate was 68. 3 %（ 43 /63）,which was obviously related to the tumor diameter（ χ^2 4. 506,P = 0. 034）,clinical stage（ χ^2 8. 866,P = 0. 012）,lymph node metastasis（ χ^2 19. 52,P〈0. 001）,and the difference was statistically significant. There was no significant correlation with gender,age,degree of differentiation,and other indicators（ P〉0. 05）. Conclusion： Eg5 in normal lung tissue,there was no obvious expression while there was high expression in non- small cell lung cancer which was closely related to its clinical stage and metastasis. Eg5 can predict the lymph node metastasis of non- small cell lung cancer and may be a potential target in its therapeutics.

关 键 词：驱动蛋白 Eg5 非小细胞肺癌 转移 

分 类 号：R734.2[医药卫生—肿瘤]